Literature DB >> 17212153

[A 42-month disease free survival case of combined hepatocellular-cholangiocarcinoma with lymph node metastases treated with multimodal therapy].

Hiromitsu Hayashi1, Toru Beppu, Takatoshi Ishiko, Takao Mizumoto, Toshiro Masuda, Kazutoshi Okabe, Yoshifumi Baba, Hirohisa Okabe, Hiroshi Takamori, Keiichiro Kanemitsu, Masahiko Hiroto, Hideo Baba.   

Abstract

Combined hepatocellular and cholangiocarcinoma (HCC-CC) is a rare type of liver cancer. We herein report a case of HCC-CC with lymph node metastases treated by multimodality therapy. The patient has been alive for more than 42 months. A 52-year-old man with a 9 cm diameter mass lesion in the liver was admitted to our hospital. The tumor was diagnosed as peripheral type of cholangiocarcinoma. Preoperative transhepatic arterial chemoenbolization (TACE) was performed. An accumulation pattern of lipiodol after TACE and an increase of serum alpha-fetoprotein led us to diagnosis of combined HCC-CC. A three segmentectomies of the liver and dissection of the local lymph nodes were performed. A histological examination of the resected specimen showed combined HCC-CC with lymph node metastases. Alpha fetoprotein, cytokeratins 7 and 19 were partially positive with immunohistochemical staining. The final diagnosis was a mixed type of combined HCC-CC. To improve a poor prognosis of combined HCC-CC, adjuvant chemotherapy with CDDP, 5 FU and radiation therapy were achieved. Fortunately, the patient is alive without any recurrence for 42 months after the operation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17212153

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  7 in total

1.  Management of combined hepatocellular-cholangiocarcinoma: a case report and literature review.

Authors:  Ming Chi; Kaidi Mikhitarian; Chanjuan Shi; Laura W Goff
Journal:  Gastrointest Cancer Res       Date:  2012-11

2.  A New Scoring Method for Personalized Prognostic Prediction in Patients with Combined Hepatocellular and Cholangiocarcinoma After Surgery.

Authors:  Feng Zhang; Keshu Hu; Bei Tang; Mengxin Tian; Shenxin Lu; Jia Yuan; Miao Li; Rongxin Chen; Zhenggang Ren; Yinghong Shi; Xin Yin
Journal:  J Gastrointest Surg       Date:  2020-04-29       Impact factor: 3.452

3.  The Predictive Value of Staging Systems and Inflammation Scores for Patients with Combined Hepatocellular Cholangiocarcinoma After Surgical Resection: a Retrospective Study.

Authors:  Chaobin He; Yize Mao; Jun Wang; Yunda Song; Xin Huang; Xiaojun Lin; Shengping Li
Journal:  J Gastrointest Surg       Date:  2018-04-17       Impact factor: 3.452

4.  A case of combined hepatocellular-cholangiocarcinoma with favorable response to systemic chemotherapy.

Authors:  Gun Min Kim; Hei-Cheul Jeung; Dokyung Kim; Joo Hoon Kim; Sang Hyun Yoon; Eun Suk Jung; Sang Joon Shin
Journal:  Cancer Res Treat       Date:  2010-12-31       Impact factor: 4.679

Review 5.  Combined hepatocellular cholangiocarcinoma: Controversies to be addressed.

Authors:  An-Qiang Wang; Yong-Chang Zheng; Juan Du; Cheng-Pei Zhu; Han-Chun Huang; Shan-Shan Wang; Liang-Cai Wu; Xue-Shuai Wan; Hao-Hai Zhang; Ruo-Yu Miao; Xin-Ting Sang; Hai-Tao Zhao
Journal:  World J Gastroenterol       Date:  2016-05-14       Impact factor: 5.742

6.  Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma.

Authors:  Satoshi Kobayashi; Takeshi Terashima; Satoshi Shiba; Yukio Yoshida; Ikuhiro Yamada; Shouta Iwadou; Shigeru Horiguchi; Hideaki Takahashi; Eiichiro Suzuki; Michihisa Moriguchi; Kunihiro Tsuji; Taiga Otsuka; Akinori Asagi; Yasushi Kojima; Ryoji Takada; Chigusa Morizane; Nobumasa Mizuno; Masafumi Ikeda; Makoto Ueno; Junji Furuse
Journal:  Cancer Sci       Date:  2018-06-27       Impact factor: 6.716

Review 7.  Therapy of Primary Liver Cancer.

Authors:  Mei Feng; Yisheng Pan; Ruirui Kong; Shaokun Shu
Journal:  Innovation (Camb)       Date:  2020-08-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.